TELA BIO, INC. : Entering into a Material Definitive Agreement, Terminating a Material Definitive Agreement, Creating a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (Form 8- K)

0

Section 1.01 Entering into a Material Definitive Agreement.

On May 26, 2022, TELA Bio, Inc. (the “Company”) entered into the Credit and Guarantee Agreement (the “New Credit Agreement”) with Mid-Cap Financial Trust, as agent (the “Agent”), and certain lending parties. The new credit agreement provides for up to $50.0 million in term loans (the “MidCap Term Loans”), consisting of a $40.0 million Tranche 1 (“Tranche 1”) and a $10.0 million Tranche 2 (“Tranche 2”). At closing, the Company borrowed $40.0 million Tranche 1 and used a portion of the proceeds to repay borrowings under the Credit Agreement, dated November 16, 2018by and between the Company and OrbiMed II, LP Royalty Opportunities (the “Existing Credit Agreement”) and intends to use the remaining proceeds to fund operations and other general corporate purposes. The Company may borrow Tranche 2 at the option of the Company upon fulfilling certain conditions, including, but not limited to, achieving $65.0 million of product net sales by the end of fiscal 2023.

Under the New Credit Agreement, the Company has provided a first ranking security interest in all existing and future Acquired Assets, including Intellectual Property, held by the Company. The New Credit Agreement contains certain covenants that limit the Company’s ability to engage in certain transactions that may be in the Company’s long-term interest. Subject to certain limited exceptions, these covenants limit the Company’s ability to, among other things:

? create, incur, assume or permit additional indebtedness to exist, or

create, contract, authorize or permit the existence of additional privileges;

? enter into any amendment, supplement, waiver or other modification of, or enter

in any forbearance to exercise any rights with respect to, the terms or

provisions contained in certain agreements without consent;

? make certain changes in the activities, exercise, management,

entity name, business locations;

? liquidate or dissolve, merge with or into, consolidate with or acquire all or

substantially all of the share capital or assets of any other company;

? pay cash dividends, make any other distributions in respect of, or redeem,

withdraw or redeem any shares in the share capital of the Company;

? make certain investments; and

? enter into transactions with affiliates of the Company.

The New Credit Agreement also contains customary indemnification obligations and events of default, including, but not limited to, (i) non-payment, (ii) breach of warranty, (iii) breach of covenants and obligations, (iv) default on other debts, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of collateral, (ix) key permit events, ( (x) termination of a pension plan, (xi) regulation (xii) material adverse effect and (xiii) breach of material contracts.

In addition, the Company must maintain minimum net income levels tested on a quarterly basis. In the event of default under the New Credit Agreement, the Company would be required to pay interest on the principal and all other due and unpaid obligations at the prevailing rate plus 2%.

MidCap Term Loans mature on May 1, 2027 and bear interest at a rate equal to 6.25% plus the higher of the one-month forward SOFR rates (as defined in the new credit agreement) or 1.0%. The Company is required to make 36 monthly interest payments commencing on June 1, 2022 (the “Interest Only Period”). If the Company meets the commitments at the end of the interest-only period, the Company will have the option to extend the interest-only period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the full principal payment due at maturity. If the Company breaches the covenants at the end of the interest-only period, the Company is required to make 24 months of straight-line amortization payments, with the full principal amount due at maturity.

Subject to certain limits, mid-cap term loans carry a prepayment charge of 3.0% of the prepaid principal amount for the first year following the mid-cap term loan closing date, 2.0 % of the principal amount prepaid for the second year following the closing date and 1.0% of the principal amount prepaid for the third year following the closing date and thereafter. The Company is also required to pay an exit fee at maturity or in the event of early redemption equal to 5% of all principal borrowings (or in the event of early redemption, the principal amount being repaid early).

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the New Credit Agreement, a copy of which is filed as an attachment to this current Report on Form 8-K.

Section 1.02 Termination of a Material Definitive Agreement.

On May 26, 2022in connection with the Company’s entering into the New Credit Agreement, as described in Section 1.01 of this Current Report on Form 8-K, the Company (i) has paid the Outstanding Balance and Charges, including Fees prepayment, under the existing credit agreement in the total amount of approximately $33.2 million and (ii) terminated the Existing Credit Agreement.

A description of the material terms of the existing credit agreement is contained in the company’s annual report on Form 10-K for the year ended
December 31, 2021 filed with the Security and Exchange Commission on March 23, 2022the description of which is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under a

          Off-Balance Sheet Arrangement of a Registrant.



The information set forth in Section 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial statements and supporting documents.




(d) Exhibits



Exhibit No.   Document
  10.1          Credit and Security Agreement, dated as of May 26, 2022, by and among
              TELA Bio, Inc., MidCap Financial Trust and the lenders from time to
              time party thereto.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Previews

Share.

About Author

Comments are closed.